RT Journal Article SR Electronic T1 Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5387 OP 5392 DO 10.21873/anticanres.12868 VO 38 IS 9 A1 KOSUKE UEDA A1 SHIGETAKA SUEKANE A1 TAISHI HIRANO A1 NAOYUKI OGASAWARA A1 KATSUAKI CHIKUI A1 KEIICHIRO UEMURA A1 MAKOTO NAKIRI A1 KIYOAKI NISHIHARA A1 MITSUNORI MATSUO A1 TSUKASA IGAWA YR 2018 UL http://ar.iiarjournals.org/content/38/9/5387.abstract AB Aim: To investigate prognostic factors for patients with advanced renal cell carcinoma (RCC) treated with axitinib as second-line therapy. Patients and Methods: This study included 35 patients with RCC who received axitinib as second-line therapy after the failure of first-line tyrosine kinases inhibitor from November 2012 to March 2017. Results: In univariate analyses, the following factors were associated with poor prognosis: bone and extrapulmonary metastasis for progression-free survival; and prior nephrectomy, Memorial Sloan Kettering Cancer Center risk classification, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification of poor, extrapulmonary metastasis and early tumor response for overall survival. Multivariate analyses identified the following factors as independent poor prognostic effects: extrapulmonary metastasis for progression-free survival, and no prior nephrectomy, IMDC risk classification of poor and extrapulmonary metastasis for overall survival. Conclusion: Axitinib as second-line treatment is effective for patients with pulmonary metastasis alone of RCC, but not for those with extrapulmonary metastasis.